key: cord-0750422-1utz6mlj authors: Poduri, Ramarao; Joshi, Gaurav; Jagadeesh, Gowraganahalli title: Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19 date: 2020-07-22 journal: Cell Signal DOI: 10.1016/j.cellsig.2020.109721 sha: fb22015c689c751206c8b53dbf5574b6bfb4afea doc_id: 750422 cord_uid: 1utz6mlj The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense, single-stranded RNA virus that causes the potentially lethal Covid-19 respiratory tract infection. It does so by binding to host cell angiotensin converting enzyme 2 (ACE2) receptors, leading to endocytosis with the receptor, and subsequently using the host cell’s machinery to replicate copies of itself and invade new cells. The extent of the spread of infection in the body is dependent on the pattern of ACE2 expression and overreaction of the immune system. Additionally, by inducing an imbalance in the renin-angiotensin-aldosterone system (RAAS) and the loss of ACE2 would favour the progression of inflammatory and thrombotic processes in the lungs. No drug or vaccine has yet been approved to treat human coronaviruses. Hundreds of clinical trials on existing approved drugs from different classes acting on a multitude of targets in the virus life cycle are ongoing to examine potential effectiveness for the prevention and treatment of the infection. This review summarizes the SARS-CoV-2 virus life cycle in the host cell and provides a biological and pathological point of view for repurposed and experimental drugs for this novel coronavirus. The viral lifecycle provides potential targets for drug therapy. The outbreak of severe acute respiratory syndrome (SARS) first occurred in 2003 and was largely contained within six months. [1] There was a large time gap before a second, closely-related coronavirus, Middle East respiratory syndrome coronavirus (MERS-CoV) appeared in 2012. [2] This frequently caused renal failure in addition to severe respiratory disease. [3] As of November 30, 2019, the World Health Organization (WHO) had registered 2494 MERS-CoV cases worldwide. [4] The first report of SARS-CoV-2, the seventh coronavirus known to infect humans, appeared in China in December 2019. [5] As of June 9, over 7.2 million SARS-CoV-2-related cases were reported worldwide with over 409,000 deaths (https://coronavirus.jhu.edu/map.html) surpassing the combined number of cases and deaths from two previous coronaviruses. The disease, Covid-19, is characterized by a range of symptoms, primarily including fever, cough, dyspnea, and myalgia. [6] In severe cases, the most common chest computed tomography finding is bilateral lung involvement with groundglass opacity. [7] The primary cause of mortality from /Covid-19 stems from compromised immune systems, leading to respiratory failure. Many more patients have exhibited cardiovascular-related pathologies including congestive heart failure and brain medullary cardiorespiratory dysfunction and inflammatory thrombocytosis. [8] [9] [10] Covid-19 killed more people on a weekly or monthly basis in early 2020 than any other cause of death except cardiovascular disease, which has still marginally maintained the number one spot. [11] The rapid spread of the virus causing Covid-19 has sparked fear worldwide and almost all countries are dealing with a surge in confirmed cases and deaths. The disease is increasingly affecting elderly people with underlying medical issues, although no one is invulnerable regardless of age, sex, or race. patients with Covid-19. Hundreds of clinical trials of potential Covid-19-related drugs have been launched globally, including the WHO's large-scale SOLIDARITY trial. Additionally, several clinical trials to develop an effective vaccine to treat Covid-19 are underway. The journey of SARS-CoV-2 begins as it enters the nasopharynx by attaching to angiotensin-converting enzyme 2 (ACE2) receptor-enriched epithelial cells of the nasal and oral mucosa, precipitating a reduced sense of smell and taste as it passes down to the lungs, the primary site of infection. The subsequent events, including endocytosis, using the host cellular machinery for genome replication, transcription, assembly, and release of virus to other cells where it infiltrates organ systems from the brain to blood vessels to toes inflicting multiple organ damage [12] provide ample intervention sites to intercede in the progression of the disease. This review presents the argument that drug targets should be identified at each of the multiple stages of the SARS-CoV-2 life cycle. Given the pathology of the disease, in which the virus attacks more than one organ and induces a dysregulated inflammatory response, an optimally successful strategy for identifying efficacious and safe drug therapy may require a concerted and integrated approach, matching drug mechanisms of action to the respective drug targets at each stage of the virus life cycle. Exploring the repurposing of existing drugs and developing new drugs are both of considerable interest. We discuss therapeutic strategies of drugs under active investigation based on the target site and mechanism of action, and the need for evaluation of promising approaches via multisite randomized, concurrently controlled clinical trials. including furin, cathepsins, trypsin, human airway trypsin-like proteases, and transmembrane protease serine protease (2/4) (TMPRSS) have been identified that allow activation of S protein by proteolytic cleavage into subunits S1 and S2. The study by Hoffmann et al. corroborated these findings and suggested a role of TMPRSS2 in proteolytic cleavage of S protein to S1 and S2 subunits.[32] The role of S protein in CoV fusion has been well-documented in previous outbreaks. [39] The fusion of S protein with the human cell receptor allows the entry of viral genetic material to host cells, causing the invasive infection. In the previous outbreaks, it was found that CoV uses a furin activation site (FAS) to bind to the host receptor. [35] The furin and furin-like proteases are considered to be a group of proprotein convertases (type I transmembrane protein) that allow cleavage of S protein at two distinct sites, resulting in the formation of two in cardiac hypertrophy (Box 2). [62, 63] Taken together, the RAAS system is comprised of two axes: ACE-Ang II-AT-1 receptor is the predominant axis that promotes vasoconstriction, proliferation, fibrosis, oxidative stress, thrombosis, and inflammation; and the ACE2-Ang (1-7)-Mas receptor axis counterbalances the effects of Ang II as Ang (1) (2) (3) (4) (5) (6) (7) has natriuretic, endothelial protective, cardioprotective, vasodilatory, anti-inflammatory, antithrombosis, and anti-proliferative properties (Fig. 1) . [60] ACE2 is the principal control component of the protective axis as it generates those key cardioprotective and hypotensive peptides. [64] It is upregulated in failing hearts. However, in hosting SARS-CoV-2, ACE2 is now playing a pathogenic role in easing virus infection, thus limiting its protective effect in lung and heart. ACE2 internalization worsens the pulmonary and cardiac damage initially triggered by SARS-CoV-2. On the other hand, drugs that can upregulate the expression of ACE2, such as ARBs and ACE inhibitors that are extensively used in hypertensive patients and statins in hyperlipidemic patients infected with SARS-CoV-2 have strengthened activity of the protective axis relative to the ACE-Ang II-AT-1 R axis, and these patients are unlikely to be at greater risk. [9, 57, 65, 66] Once the viral RNA is released into the host cell, the ss-positive sense RNA acts as messenger RNA (mRNA) and undergoes translation by using host cell machinery. [67] The series of events also leads to the formation of enzymes involved in viral replication, which generate and assemble new viral particles. The sequence of steps is illustrated in Fig 2. The critical pathways utilized by SARS-CoV-2 include a) RNA Synthesis, b) proofreading of template, and c) capping. [68] The RNA machinery involves Nsp1-16 complex, [68, 69] among which Nsp12 (RNA dependent RNA polymerase; RdRp) [70, 71] , Nsp13 (zincbinding helicase; HEL) [72] , Nsp14-16 complex (mRNA capping) [73] , Nsp14 (RNA proofreading) [70, The RNA polymerization is catalyzed by Nsp12, in association with cofactors Nsp7-8. The N-terminal domain of Nsp12 (also referred to as Nidovirus RdRp-Associated Nucleotidyltransferase or NiRAN) is considered to be conserved in the majority of coronaviruses and possesses nucleotidylation activity. [76] The domain consists of α and β subunits (8 α helices and 5 stranded β-sheet). The β subunit possesses Serine/Threonine kinase PRP4 and Tyrosine-protein kinase JAK1 homologs that interact with the palm subdomain of the RdRp or Nsp12 and promotes viral growth. The C-terminal domain of Nsp12 is known to possess catalytic aspartic acid residues (Asp618, Asp623 Asp760, and Asp761) and are involved in recognition of nucleoside triphosphate and other divalent cation(s)(Mg 2+ ) to perform the catalytic role (initiation and elongation) in viral growth. [71] Furthermore, RNA proofreading and mRNA capping occur in conjunction with the bifunctional protein Nsp14. It contains two domains; the N terminal domain possesses exoribonuclease activity (DEDD exonucleases family) involved in proofreading, whereas the C terminal domain has (N 7 guanine)-methyl transferase activity involved with viral mRNA cap synthesis. The cap consists of an N 7 -methylated GTP molecule linked 5′-5′ triphosphate bond transcribed by the first nucleotide. [70, 74] The capping machinery apart from Nsp14 consists of Nsp13, 16, and cofactor Nsp10. [77, 78] The capping is considered vital for mRNA stability and evading host immune response. The mRNA capping is initiated with multifunction Nsp13, which plays the role of helicase (nucleoside triphosphate enzymes (NTPs)) and plays a crucial role in virus replication. The Nsp13 is involved with the hydrolysis of NTPs, unwinding of RNA duplexes with 5'-3' directionality along with RNA 5'triphosphatase activity. [72] Finally, the termination of mRNA capping is done by Nsp16 in complex with Nsp10. Nsp16 is known to belong to a class of O-methyl Transferase characterized by reversed β hairpin at the carboxyl end. Finally, the processes catalyzed by Nsp13 (helicase), Nsp14 (GTPase), Nsp15 (N7-Methyl Transferase), and Nsp16 (2'-O-Methyl Transferase) activities leads to the synthesis of a nascent RNA strand possessing cap1 structure at its 5′ end terminal. [74, 79] The host endoplasmic reticulum and Golgi apparatus further facilitate the assembly of viral RNAs and associated proteins into virions (SARS-CoV-2 virus). [80] The M and E proteins interact together to form virus-like particles, whereas the N protein enhances their formation in the endoplasmic reticulum and Golgi apparatus. The S protein, however unimportant, is also incorporated into the new virions. J o u r n a l P r e -p r o o f Journal Pre-proof The virus release from an infected cell primarily occurs via budding, exocytosis, or cell death. Mechanistically, for undeveloped virion particles, budding occurs. N protein interacts with the host cell membrane region where the viral E protein (glycosylated) has been inserted. Importantly, the N protein allows a proper orientation for budding of virion at the plasma membrane, endosomal, nuclear, or perinuclear membranes leading to the release of virus particles. The viruses that become matured at the endoplasmic reticulum or Golgi apparatus are released via exocytosis. In many cases, the virus attack destroys the host cell machinery leading to the release of lysosomes: this disruption of cell integrity results in cell death and consequent release of virus particles. [80, 81] Finally, these progeny virions get released out of the host cell in vesicles by exocytosis. These newly released virions may either infect other healthy cells or shed into the environment via the opening of the mouth, breathing, or similar occurrences that may infect healthy persons via reported modes of transmission. [77, 78] At present, there are no drugs approved for the treatment of patients with Covid-19. [82] The pandemic that was set in the early months of 2020 worldwide has triggered an unprecedented stampede into hundreds of clinical trials evaluating both approved or licensed drugs and investigational agents. [83] All of these clinical trials are based on keeping in mind the viral life cycle, from the host cell attachment and entry to translation, replication and release, and the subsequent damage resulting from the compromised immune system. [84] Thus, there are multiple targets to consider for potential therapeutic intervention. Covid-19 is more than a lung infection as imaging and pathological investigations show that the syndrome is a thrombo-inflammatory process that initially affects lung perfusion, but consecutively affects all organs of the body. [85] Thus, a combination of drugs encompassing more than one target could potentially yield better results. [86] to hair loss), Sildenafil (from angina to erectile dysfunction), Thalidomide (from morning sickness to leprosy and multiple myeloma), Ketoconazole (from fungal infections to Cushing syndrome); Aspirin (from analgesia to colorectal cancer), Paromomycin (from antibiotic in acute and chronic intestinal amebiasis to visceral and cutaneous leishmaniasis). [90] Doxycycline (from broad-spectrum bacteriostatic to antimalarial agent) [91] , Miltefosine (from breast cancer to visceral leishmaniasis) [92] , Allopurinol (antineoplastic to gout), and Bromocriptine (from initial use in Parkinson's disease to Type 2 diabetes). [93] The relevant repurposing data in SARS-CoV-2 is led by computational approaches and prior knowledge of previous pandemics. Computational methods, including proteinprotein interaction models, enrich evaluation of the target profile of small molecules, allowing the possibility of already approved drugs being found useful. [88, 89] In this context, Joshi and Poduri have screened 8548 ligands (approved, investigational, and experimental drugs) on endoribonuclease NendoU (Nsp-15) via virtual screening and molecular modeling. The study showed eprosartan (AT-1 receptor blocker approved for the treatment of hypertension), investigational drugs DB15063 (Inarigivir soproxil), and DB12307 (Foretinib), and an experimental drug DB01813 are promising drugs for further evaluation in the treatment of Covid-19. [94] Drugs under consideration that could have activity for Covid-19, such as antivirals, protease inhibitors, antibiotics, statins, RAAS inhibitors, corticosteroids, antirheumatics, and antineoplastic, are listed in Table 1 . Various classes of drugs including anti-inflammatory, immune modulators, and anesthetics are being evaluated preclinically or into clinical trials to assess their possible repurposing for 96] Therefore, drug repurposing is a potentially fast and reasonable strategy to discover new treatments from existing drugs, and may reduce the cost compared to de novo drug discovery. [97] However, for repurposed drugs, a benefit-risk profile in clinical trials may fail for any new indication. Other aspects such as selecting appropriate doses that affect the dose-response relationship may also be taken into consideration. [98] [99] Therefore, newer development using repurposed drugs will depend not only on regulatory evidence of efficacy, safety, and quality but also on comparative cost-effectiveness and comparative clinical efficacy. [98, 100, 101] subsequent TMPRSS2-dependent entry into host cells. [32] The blockade of these pathways might reduce the virus titer of SARS-CoV. Proprotein convertase inhibitor α1-PDX is demonstrated to inhibit cleavage activity. [103] Serine protease inhibitor camostat mesylate, which blocks TMPRSS2 activity, has been shown to significantly reduce MERS-S-, SARS-S-, and SARS-2-S-driven entry into the lung cells. [32] It has been approved in Japan for chronic pancreatitis and could be considered for clinical trials in the treatment of SARS-CoV-2-infected patients. [104] Much of the effort to develop vaccines and diagnostic tests has focused on a spike protein. However, other proteins might also be important determinants of immunity against SARS-CoV-2. [59] 4.2 Modulating SARS-CoV-2 receptor ACE2: As discussed earlier, SARS-CoV-2 exploits ACE2 for cellular entry with higher efficiency than SARS-CoV. This process induces the internalization of ACE2 that could cause loss of pulmonary function and increased tissue fibrosis as a result of elevated levels of circulating Ang II. [57, 105] In the absence of ACE2, all available Ang I is converted to Ang II. Drugs that target various components of the RAAS such as ACE inhibitors, ARBs, aldosterone antagonists augmenting ACE2 activity or expression, and the product of ACE2 such as Ang (1) (2) (3) (4) (5) (6) (7) , are subject to several clinical trials (Table 1) . [106, 107] Drugs that bind to ACE2 receptor: One of the measures that could successfully compete with endogenous ACE2 is soluble ACE2 [56, 108] or an Fc domain fused to ACE2 that may act as a decoy to direct SARS-CoV-2 away from endogenous ACE2 and itself bind the invading virus. The soluble form floats in the bloodstream and may act as a competitive interceptor of SARS-CoV-2 from binding to the full length ACE2 anchored in the cell membrane (Fig. 3) . This prevents the virus from multiplying and damaging the cells. respiratory distress syndrome. [110] Another strategy that is being investigated in clinical trials is the administration of an antibody or a single chain antibody fragment (scFv) that binds ACE2 and blocks the interaction of spike protein on the virion to ACE2. [111] The small intestine secretes two kinds of α defensins, HD5 and HD6. [ and pulmonary epithelial cells. [116] ARBs are known to decrease hypoxiainduced cell damage. [117] RAAS inhibitors: Experimental studies have shown that Ang II overactivation of the AT-1 receptor activates metalloprotease A Disintegrin And Metalloprotease 17 (ADAM-17), also known as tumor necrosis factor-α converting enzyme (TACE), cleaves ACE2, which can no longer catalytically convert Ang II or Ang I to protective peptides (Ang (1-9) and Ang (1-7), respectively). This is one of the mechanisms that contribute to myocardial dysfunction and hypertension. [118] The cleaved ACE2 is endocytosed and degraded in lysosomes. With coronavirus infection, ACE2 is downregulated, causing increased levels of Ang II [105] , the generator of a few inflammatory molecules. Limiting the synthesis of protective peptides may magnify the cytokine storm, resulting in acute lung injury, and overwhelming inflammatory response. [119] High cytokine levels may represent the leading cause of myocardial injury and endothelial dysfunction in patients with Covid-19 infection. [51] Although no evidence of histologically confirmed Covid-19 myocarditis has been published, [51] elevated plasma troponin and N-terminal pro-B-type natriuretic peptide levels with a significant (P <0.001) positive linear correlation with plasma high sensitivity C-reactive protein levels showing myocardial injury have been reported. [119] [120] [121] Rarely, the patient presents with electrocardiogram changes (acute ST-elevation myocardial infarction). [122] These results suggest that cardiac injury is a common condition among hospitalized patients with Covid-19 and it is associated with a higher risk of in-hospital mortality compared with lack of cardiac injury (P <0.001). [120] In non-clinical studies, treatments with ARBs, ACE inhibitors, and aldosterone receptor antagonists strengthen the activity of the protective axis as these drugs upregulate J o u r n a l P r e -p r o o f Journal Pre-proof the expression of ACE2. [57, 106, 123, 124] (Fig. 3 ) and increase the production of Ang (1-7) by NEP on Ang I. Additionally, ACE inhibitors prevent the metabolism of Ang (1-7) to the inactive metabolite, Ang (1) (2) (3) (4) (5) . However, it is not known whether RAAS inhibitor therapy increases ACE2 expression in patients. Based on preclinical studies, it is postulated that continuous therapy with RAAS inhibitors might cause an increased rate of cellular infection by a predicted compensatory induction of more ACE2 viral receptor sites and hence accelerate the spread of Covid-19 in an infected lung. However, it is unlikely to happen in the presence of AT-1 receptor blockade. [38] The compensatory increase of Ang II is a) unlikely to produce any inflammatory or oxidative responses; b) engaged by ACE2 to form Ang (1-7), and the operation might go in parallel with the virus binding ACE2 until it is internalized as their loci on ACE2 is different and do not compete with each other. [58] There are no studies in humans demonstrating the effects of RAAS inhibitors on pulmonary or cardiac ACE2 expression and activity. Several reports coming from hospitals having acute inpatients with Covid-19 have observed that treatment with ARBs or ACE inhibitors was not associated with an increased risk of rapidly deteriorating severe disease. [125] A recent clinical study [9] observed an association of reduced all-cause mortality of Covid-19 patients with hypertension. Based on the analysis of 1128 hospitalized Covid-19 patients with hypertension, the investigators reported that the mortality rate was lower in the ACE inhibitors/ARBs group versus the non-ACE inhibitors/ARBs group (3.7% vs. 9.8%; P = 0.01). In another study, patients on ACE inhibitors/ARBs had statistically significantly lower levels of hypersensitive C-reactive protein and procalcitonin when compared with patients not receiving an ACE inhibitor/ARB, but with no effect on mortality [65] , suggesting a potential anti-inflammatory function of RAAS inhibitors in Covid-19. This was substantiated in another study [126] wherein the absolute number of CD3+ and CD8+ T cells were statistically significantly higher in the ACE inhibitor/ARB group than in the non-ACE inhibitor/ARB group. Furthermore, there was a trend toward lower interleukin-6 levels in patients from the ACE inhibitor/ARB group. These findings support the fact that Ang II regulates the expression of inflammatory cytokines through the activation of AT-1 receptors. [127] RAAS inhibitors attenuate that inflammatory response and Similarly to hypertension, atherosclerosis [66, 128] , and hypoxia/high altitude [114] are also associated with reduced ACE2 expression. Statins have been shown to increase ACE2 expression in the heart and kidneys of rabbits fed a high cholesterol diet. [129] Additionally, PPARᵞ may also influence ACE2 expression as rosiglitazone and telmisartan (an ARB with a partial PPARᵞ agonist activity) have been shown to increase ACE2 expression in the aorta of hypertensive rats. Some warranted, clinical trials are already in progress to evaluate the impact of treatment with RAAS inhibitors, Ang (1-7), and statins (Table 1) given that these classes of drugs enhance ACE2, which in part contributes to the benefit of these regimens for Covid-19-related pathologies such as acute and chronic respiratory disease. Upon entrance to the host cells, the viral genome is released as a single-stranded positive RNA. Subsequently, it is translated with a ribosomal frameshifting mechanism generating two polyproteins, pp1a and pp1ab. Encoded within the polyproteins are two proteinases, 3chymotrypsin-like proteinase (3CLpro, also called main protease Mpro) and papain-like proteinase (PLpro). Both of these proteases are responsible for the cleavage of polyproteins translated from viral RNA into functional or effector proteins for virus replication and packaging within the host cells. [130] Inhibiting the activity of this enzyme would block viral replication. PLpro behaves as a deubiquitinase that may deubiquitinate certain host cell proteins such as interferon and NF-κB, resulting in suppression of the innate immune system. [65] Both are considered to be attractive drug targets as they play a central role in viral replication and transcription functions through extensive proteolysis of two replicase polyproteins, pp1a and pp1ab. Drugs that target these proteases in other viruses, such as the HIV/AIDS drugs lopinavir and ritonavir (Fig. 3) , have been explored in combination in patients with mild and J o u r n a l P r e -p r o o f moderate Covid-19 (Table 1) . However, no benefit was observed with the treatment. [131] The efficacy of combination therapy of lopinavir/ritonavir and interferon β1b is being studied in a clinical trial. [132] A recently published X-ray crystal structure of the SARS-CoV-2 3CLpro provides a basis for structure-based drug discovery efforts. [133] A different class of drugs has been shown to inhibit viral replication in cells. Carmofur (1-hexylcarbamoyl-5fluorouracil), an approved anticancer agent indicated for colorectal cancer since the 1980s, has been shown to inhibit the main protease Mpro activity (). [134] Besides, a large number of inhibitors of these proteinases have been investigated in nonclinical studies, and are described in several publications. The life cycle of the virus is dependent on enzymes that are excellent antiviral drug targets. One of the major viral enzymes that assist in translation and replication of the virus is RNAdependent RNA polymerase. It is the major target of many existing nucleotide drugs such as remdesivir, favipiravir, ribavirin, galidesivir, and EIDD-2801 ( The invasion of the ACE2 receptor rich alveolar epithelial cells in the lung by the virus leads to the exuberant stimulation of the immune system, triggering a cytokine storm. Cytokines are chemical signaling molecules that essentially guard a healthy immune system. Thus, it should beat back the virus attack at the initial stages before the virus runs through the windpipe and invades the lungs and setting in motion the cytokine storm. This event causes a plethora of effects such as lung and cardiovascular damage, metabolic acidosis, coagulation dysfunction, septic shock, and multiple organ failure. [137, 138] The inflammatory response to the virus is excessive, resulting in the onset of a cytokine storm [12] with an increase in inflammation-inducing cytokines such as IL-2, IL-6, IL-7, granulocyte colony stimulating factor, and tumour necrosis factor-α (TNF-α). [65] The cytokine storm also leads to secondary hemophagocytic lymphohistiocytosis (sHLH) and tissue damage. antagonists increase the risk of infections [149] and might suppress the immune response that the body needs to fight off the virus. [12] Several clinical trials are in progress to determine the beneficial effects of tocilizumab, sarilumab, and siltixumab (Table 1) . NLRP3 has a major role in regulating innate immunity. Its activation occurs in response to invading pathogens including RNA viruses. It activates caspase-1 to produce the pro- Journal Pre-proof The SARS-CoV-2 pandemic created havoc in the world and everyone is eagerly awaiting the arrival of a vaccine for Covid-19. The critical step for the successful development of a vaccine is the identification of the complete genome sequence of the pathogen. This information was made available on 25 th January 2020 at NCBI (Gen. Bank: MN 908947.3) . A detailed account of the difference between traditional vaccine development and development using the pandemic paradigm is reported. [155] The pandemic paradigm requires multiple activities to be conducted at financial risk to developers and manufacturers and without knowing whether the vaccine candidate will be safe and effective, including a very early manufacturing scale-up to commercial scale before the establishment of clinical proof of concept. authorities throughout the world and developers of vaccines. Owing to the high similarity of SARS-COV-2 with SARS-COV and the binding pattern to ACE2 receptors in the host cell, the pandemic has unlocked the scope for the development of vaccines and biopharmaceuticals at a more rapid pace than ever before. [156] These biologics are expected to broaden the spectrum of the current treatment options available. [ Oligonucleotides; e) hematopoietic growth factors; and f) interleukin-based products. The detailed classification, the mechanism of action of each biologic, and their clinical status are compiled in Supplementary Table 2 . These are chiefly intended to target the most fragile and vulnerable sites/receptors expressed on viral surfaces (monoclonal antibodies), [160] provide antiviral immunity along with possessing immunomodulatory properties (interferons), [161] potentially interfere with the spike protein or replicative machinery of the virus (oligonucleotides), [162] enhance the production of hematopoietic cells (hematopoietic growth factors) [163] or via blocking key immune players (interleukin based products). [164] [60] P. Balakumar, G. Jagadeesh, A century old renin-angiotensin system still grows with  ACE2 is widely expressed in most of the organs, beginning with nose and throat and from head to the gut and testicles. ACE2 converts decapeptide Ang I and octapeptide Ang II to nonapeptide, Ang (1-9), and heptapeptide, Ang (1-7) , respectively. [58]  ACE2 actions are non-specific as it also cleaves and inactivates bioactive apelin peptides apelin-13 and apelin-36 through a negative feedback mechanism in the heart and vasculature [56] and also des-arginine bradykinin to bradykinin. Additionally, it is an amino acid transporter.  ACE2/Ang 1-7/MasR axis is a physiological antagonist that counter-regulates the activated RAAS. Thus, ACE2 is a critical protective pathway against heart failure, myocardial infarction and hypertension, and against lung disease and diabetes mellitus. [56]  There are two forms of ACE2, the full-length ACE2 containing structural domain anchors its extracellular domain to the cell membrane, and the soluble form lacking the membrane anchor circulates in undetectable quantity in the blood. [53, 163] The both forms of ACE2 comprise the N-terminal protease domain with which the spike glycoprotein (S1) of SARS-CoV-2 binds. The catalytic site which is distinct from the protease domain catalyses Ang I and Ang II (Fig 1) . [55, 56]  Following binding by SARS-CoV-2, ACE2 is endocytosed. The loss of ACE2 function results in elevated levels of circulating Ang II.  ACE2 expression is increased by RAAS inhibitors and statins. J o u r n a l P r e -p r o o f  Ang (1-7) is a major component of the protective arm of the Renin-Angiotensin-Aldosterone System, ACE2-Ang (1-7)-Mas R axis, considered as an 'angel' in the RAAS cascade.  Ang II has a high affinity for ACE2 to form Ang (1-7) , which is also being formed by the action of ACE on Ang (1-9) and by the action of NEP on Ang I (see Fig. 1 ).  The physiological functions of Ang (1-7) are mediated through the Mas and MrgD receptors; both are G protein-coupled receptors distributed in numerous cardiovascular-related tissues. Ang (1-7) is also a biased agonist of the AT-1 receptor with a protective action in cardiac hypertrophy. [60]  Ang (1-7) is reported to produce effects opposite to that of Ang II, the major pressor hormone of the system, and it counterbalances the adverse actions of Ang II on the heart, kidney, and blood vessels.  Nearly a dozen clinical trials are ongoing investigating cardiovascular effects and, more recently on ARDS in Covid-19 patients (see Table 1 ). J o u r n a l P r e -p r o o f Anti-inflammatory It is approved to treat rheumatoid arthritis. It alleviates inflammation of the lungs by suppressing cytokine storm (reduces IL-6 and TNFα). Phase II NCT: 04335071 [196, 197] Sarilumab Anti-inflammatory Phase III NCT:04327388 [201] J o u r n a l P r e -p r o o f Siltuximab Anti-inflammatory NA NCT: 04322188 [202, 203] Ruxolitinib Anticancer Inhibit the mediation of cytokine and growth factor signaling by inhibiting JAK 1 and 2, which otherwise affect immune function and hematopoiesis. Phase II NCT:04331665, 04334044 [204] Baricitinib Anticancer It selectively and reversibly inhibits tyrosine-protein kinase Janus associated kinases 1 and 2 to modulates their signalling pathways, thereby reduce the phosphorylation and activation of STATs leading to inhibition of cytokine and chemokine transcription and thereby modulate the immune response. Currently, it is approved for the treatment of rheumatoid arthritis. Also, a clinical trial in combination with remdesivir has been initiated. Fingolimod Immunomodulator It is under clinical trial for treating multiple sclerosis. Structurally, it resembles lipid sphingosine-1-phosphate (S1P). It is a potent functional antagonist of S1P1 receptors in lymph node T cells. It suppresses the exit of lymphocytes from lymph node T cells, thus reducing the inflammation and attenuates immunopathogenesis. In Covid-19 patients, it is known to decrease pulmonary edema and hyaline membrane formation, thus preventing ARDS associated with the disease. Fluvoxamine Anti-depressant It inhibits the uptake of 5-HT by blood platelets and brain synaptosomes. It is under trial to prevent more severe complications like shortness of breath in Covid-19 patients action and serve as potential therapies in Covid-19. In addition, ACE inhibitors prevent the metabolism of Ang (1-7) by ACE to the inactive metabolite Ang (1-5) (see Table 1 ). From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia In-vitro renal epithelial cell infection reveals a viral kidney tropism as a potential mechanism for acute renal failure during Middle East Respiratory Syndrome (MERS) Coronavirus infection Coronavirus disease 2019 ( COVID-19) : situation report SnapShot: COVID-19 Clinical features of patients infected with 2019 novel coronavirus in Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study Prevalence and prevention of cardiovascular disease and diabetes mellitus A rampage through the body Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China Coronaviruses: an overview of their replication and pathogenesis Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles' heel conserved region to minimize probability of escape mutations and drug resistance The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic Tlymphocyte epitopes Docking Server: An interactive server for docking small molecules, peptides and antibodies against potential targets of COVID-19 SARS-CoV-2-encoded nucleocapsid protein acts as a viral suppressor of RNA Coronavirus hemagglutinin-esterase and spike proteins co-evolve for functional balance and optimal virion avidity On the origin and continuing evolution of SARS-CoV-2 Nextstrain: real-time tracking of pathogen evolution Distinct Viral Clades of SARS-CoV-2: Implications for Modeling of Viral Spread Analysis of codon usage and evolutionary rates of the 2019-nCoV genes Structural basis of receptor recognition by SARS-CoV-2 Genotype and phenotype of COVID-19: Their roles in pathogenesis COVID-19 and the cardiovascular system Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2 The proximal origin of SARS-CoV-2 The SARS-CoV-2 Exerts a Distinctive Strategy for Interacting with the ACE2 Human Receptor SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells Structural Basis of SARS-CoV-2 Spike Protein Priming by TMPRSS2, bioRxiv Cellular entry of the SARS coronavirus Repurposed Single Inhibitor for Serine Protease and Spike Glycoproteins of SAR-CoV-2 Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus SARS-CoV-2 (COVID-19) by the numbers The protein expression profile of ACE2 in human tissues Knowledge synthesis from 100 million biomedical documents augments the deep expression profiling of coronavirus receptors Elevated troponin in patients with Coronavirus Disease 2019 (COVID-19): possible mechanisms ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome Understanding of COVID-19 based on current evidence A novel angiotensin-converting enzymerelated carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 Prevention of Angiotensin II-Dependent Hypertension Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? COVID-19, ACE2, and the cardiovascular consequences Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary -7) peptide acts as a natural-biased ligand at the angiotensin II type 1 receptor Renin-angiotensin-aldosterone: An inclusive, an invigorative, an interactive and an interminable system Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study ACE2 activity was increased in atherosclerotic plaque by losartan: Possible relation to anti-atherosclerosis The Architecture of SARS-CoV-2 Transcriptome Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Nidovirales: evolving the largest RNA virus genome Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites Structure of the RNA-dependent RNA polymerase from COVID-19 virus SARS-coronavirus-2 nsp13 possesses NTPase and RNA helicase activities Interplay of mRNA capping and transcription machineries A Structural View at SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping Ysrafil, Severe Acute Respiratory Syndrome Coronavirus An overview of viral structure and host response Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major antiviral drug target Coronavirus SARS-CoV-2 is the Newly Emerged Zoonotic Virus Causing Pandemic Death and Economic Loss COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses Structural Basis of RNA Cap Modification by SARS-CoV-2 Coronavirus, bioRxiv Properties of Coronavirus and SARS-CoV-2 Exosome Release and Secretory Autophagy: The Autophagic-and Endo-Lysosomal Systems Go Extracellular Discovering drugs to treat coronavirus disease 2019 (COVID-19) Treating COVID-19-off-label drug use, compassionate use, and randomized clinical trials during pandemics Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19) Clinical trials on drug repositioning for Drug repurposing: progress, challenges and recommendations Drug Repurposing in Antiviral Research: A Current Scenario Drug repurposing and the medicinal chemist Topical paromomycin with or without gentamicin for cutaneous leishmaniasis Centers for Disease, Prevention, Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis Old drugs, new tricks Virtual screening enabled selection of antiviral agents against Covid-19 disease targeting coronavirus endoribonuclease NendoU: Plausible mechanistic approach to identify promising inhibitors against 3C-like Proteinase and 2 Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 Overcoming the legal and regulatory barriers to drug repurposing A bibliometric review of drug repurposing Predictive methods in drug repurposing: gold mine or just a bigger haystack? Understanding the cell biology of SARS-CoV-2 endocytosis for COVID-19 drug repurposing: looking beyond chloroquine A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin Identification of nafamostat as a potent inhibitor of Middle East respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury Angiotensin-(1-7): Translational Avenues in Cardiovascular Control Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2 Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China, F1000Res Paneth cell antimicrobial peptides: topographical distribution and quantification in human The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak Neuroprotective effects of angiotensin receptor blockers EDITORIAL [Hot Topic-II: PPAR Ligands and Cardiovascular Disorders: Friend or Foe (Guest Editors: Pitchai Balakumar and Gowraganahalli Jagadeesh) Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan Laboratory abnormalities in patients with COVID-2019 infection Corona Virus Disease 2019 (COVID-19) Presenting as Acute ST Elevation Myocardial Infarction Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2 Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker Association of Renin-Angiotensin System COVID-19 patients with hypertension Crosstalk between inflammation and angiotensin II: studies based on direct transfection of cardiomyocytes with AT1R and AT2R cDNA Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Severe COVID-19: A Review of Recent Progress with a Look Toward the Future COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Chinese Clinical Guidance For COVID-19 Pneumonia Diagnosis and Treatment Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19 The Use of Antimalarial Drugs against Viral Infection Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+ CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus IL-6/IL-6 receptor system and its role in physiological and pathological conditions Interleukin-6: A Masterplayer in the Cytokine Network COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD COVID-19: the new challenge for rheumatologists Selective JAKinibs: prospects in inflammatory and autoimmune diseases New players in the field of immune-mediated diseases Baricitinib as potential treatment for 2019-nCoV acute respiratory disease Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of the macrophage activation syndrome: Re-analysis of a prior Phase III trial Greek study in the effects of colchicine in Covid-19 complications prevention (GRECCO-19 study): Rationale and study design Developing Covid-19 vaccines at pandemic speed The SARS-CoV-2 Vaccine Pipeline: an Overview, Current tropical medicine reports (2020) 1-4 The Science Advisory Board SARS-CoV-2 Vaccines: Status Report Immunological mechanisms of vaccination A human monoclonal antibody blocking SARS-CoV-2 infection Regulation of interferon production as a potential strategy for COVID-19 treatment Oligonucleotides and the COVID-19 Pandemic: A Perspective Hematological findings and complications of COVID-19 Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? A Large-scale Drug Repositioning Survey for SARS cellular protease TMPRSS2 for entry into target cells Clinical trials on drug repositioning for COVID-19 treatment Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges Coronavirus Disease A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Angiotensin-(1-7): Translational Avenues in Cardiovascular Control Blockade of SARS-CoV-2 infection by recombinant soluble ACE2 Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Angiotensin 1-7: A peptide for preventing and treating metabolic syndrome Substituting angiotensin-(1-7) to prevent lung damage in SARSCoV2 infection? Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19 Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19 Antihypertensive drugs and risk of COVID-19? Inhibition of Viral Macrodomain of COVID-19 and Human TRPM2 by losartan A potential protective role of losartan against coronavirus-induced lung damage Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19 Statins in coronavirus outbreak: it's time for experimental and clinical studies Lipid-lowering therapy and reninangiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic Statin therapy in COVID-19 infection Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies vitro testing of Hydroxychloroquine and Azithromycin on SARS-CoV-2 shows 1 synergistic effect Lopinavir/ritonavir: A rapid review of effectiveness in COVID-19 Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study Compassionate use of remdesivir for patients with severe COVID-19 HBV replication inhibitors Triphosphates of the Two Components in DESCOVY and TRUVADA are Inhibitors of the SARS-CoV-2 Polymerase, bioRxiv The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15, bioRxiv A Case of Coronavirus Disease 2019 Treated With Ciclesonide Small Molecule Inhibitors of CRM1 The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets Use of siltuximab in patients with COVID-19 pneumonia J o u r n a l P r e -p r o o f requiring ventilatory support Interleukin-6 blockade for severe COVID-19, medrxiv COVID-19: combining antiviral and anti-inflammatory treatments Prevent COVID-19 Severity by Repurposing mTOR Inhibitors A new clinical trial to test high-dose vitamin C in patients with COVID-19 High-dose intravenous vitamin C treatment for COVID-19 Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy COVID-19): A Medicine with a Thousand Faces Home NO Therapy for COVID-19 Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, The Lancet The winner will be the one who controls that chaos Could CGRP antagonists be helpful in the fight against COVID-19? The Agent and Host Factors in Covid-19: Exploring Pathogenesis and Therapeutic Implications Identification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning Assessing nitrogen dioxide (NO2) levels as a contributing factor to the coronavirus (COVID-19) fatality rate Safety and efficacy of different anesthetic regimens for parturients with COVID-19 undergoing Cesarean delivery: a case series of 17 patients Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2 Ongoing clinical trials for the management of the COVID-19 pandemic We thank Drs. J. Rick Turner and Monika Deshpande for a review of the manuscript. The authors declare that they have no competing financial interests. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.